Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters











Database
Type of study
Language
Publication year range
1.
Clin Appl Thromb Hemost ; 8(2): 169-77, 2002 Apr.
Article in English | MEDLINE | ID: mdl-12121059

ABSTRACT

Acetylsalicylic acid inhibits thromboxane A2 production and reduces the risk of vascular occlusive events by 20% to 25%. Ticlopidine inhibits ADP-dependent platelet aggregation and reduces the same risk by 30% to 35%, but produces some adverse effects. Clopidogrel is a ticlopidin-related antiplatelet drug, with the same mechanism of action; it reduces the expression of the glycoprotein IIb/IIIa, the fibrinogen receptor on the platelet surface. Clopidogrel has the same clinical efficacy of ticlopidin and has a decreased incidence of adverse effects. The effect of one daily dose of 75 mg of clopidogrel on platelet function in 90 subjects was evaluated; 41 with coronary artery disease and 49 with cerebral vascular disease. Before treatment and after 6 and 12 weeks, bleeding time and fibrinogen plasma concentration were also evaluated. There was a reduction in 5-microM ADP-induced platelet aggregation of 38%+/-27% at 6 weeks and 44%+/-29% at 12 weeks in patients with coronary artery disease; 35%+/-41%, 29%+/-59% in the cerebral vascular disease group; and 36%+/-36% and 35%+/-49% in the total group. Reduction of 20 microg/mL collagen-induced platelet aggregation was not significant in any group. Plasma fibrinogen levels did not vary during treatment. Bleeding time was significantly prolonged in all studied groups. There were no hemorrhagic complications; only digestive discomfort in less than 3% of patients. Clopidogrel efficiently reduces ADP-induced platelet aggregation and prolongs bleeding time and is a safe and efficacious antiplatelet drug.


Subject(s)
Clopidol/administration & dosage , Coronary Artery Disease/drug therapy , Fibrinogen/drug effects , Intracranial Arteriosclerosis/drug therapy , Platelet Aggregation/drug effects , Adenosine Diphosphate/pharmacology , Adult , Aged , Aged, 80 and over , Clopidol/pharmacology , Clopidol/toxicity , Collagen/pharmacology , Coronary Artery Disease/blood , Coronary Artery Disease/etiology , Family Health , Humans , Intracranial Arteriosclerosis/blood , Intracranial Arteriosclerosis/etiology , Male , Middle Aged , Platelet Function Tests
2.
Environ Health Perspect ; 18: 167-79, 1976 Dec.
Article in English | MEDLINE | ID: mdl-1037611

ABSTRACT

Four veterinary drugs of dissimilar chemical structures were evaluated for environmental stability and penchant for bioaccumulation. The techniques used were (1) a model aquatic ecosystem (3 days) and (2) a model feedlot ecosystem (33 days) in which the drugs were introduced via the excreta of chicks or mice. The model feedlot ecosystem was supported by metabolism cage studies to determine the amount and the form of the drug excreted by the chicks or mice. Considerable quantities of all the drugs were excreted intact or as environmentally short-lived conjugates. Diethylstilbestrol (DES) and Clopidol were the most persistent molecules, but only DES bioaccumulated to any appreciable degree. Phenothiazine was very biodegradable; sulfamethazine was relatively biodegradable and only accumulated in the organisms to very low levels. Data from the aquatic model ecosystem demonstrated a good correlation between the partition coefficients of the drugs and their accumulation in the fish.


Subject(s)
Clopidol/metabolism , Diethylstilbestrol/metabolism , Phenothiazines/metabolism , Pyridines/metabolism , Sulfamethazine/metabolism , Animals , Chickens , Chlorophyta , Clopidol/toxicity , Culex , Cyprinodontiformes , Daphnia , Diethylstilbestrol/toxicity , Ecology , Environmental Exposure , Feces/analysis , Mice , Phenothiazines/toxicity , Snails , Sulfamethazine/toxicity
SELECTION OF CITATIONS
SEARCH DETAIL